Medical Marijuana Inc. Investment AXIM® Biotech Announces …

NEW YORK – (Uptick Newswire – March 8, 2017) – Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being conducted by Renger Witkamp, Professor and Chair in Nutrition and Pharmacology, at Wageningen University in the Netherlands.

Selected from a pool of over 400 patients, 40 trial patients aged 18-65 will be subject to a randomized, double-blind, cross-over trial of 8 weeks. Patients will receive a maximum 6 chewing gums per day, either containing 50 mg of cannabidiol per chewing gum in case of the CanChew chewing gum, or a placebo chewing gum.

Final data collection for primary outcome measure is

... read more at: https://upticknewswire.com/medical-marijuana-inc-investment-axim-biotech-announces-enrolled-patients-begin-phase-ii-trial-treatment-irritable-bowel-syndrome-ibs-canchew-plus-cannabidiol-cbd-chew/